<DOC>
	<DOCNO>NCT00507962</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose cisplatin give liposomal doxorubicin treatment advance cancer involve liver . PRIMARY Objectives : To determine toxicity safety monthly cytotoxic regimen combine intraarterial hepatic ( HAI ) cisplatin systemic intravenous liposomal doxorubicin patient cancer metastatic liver . SECONDARY Objectives : To document descriptive fashion antitumor efficacy monthly hepatic intraarterial cisplatin combination systemic liposomal doxorubicin .</brief_summary>
	<brief_title>Cisplatin HAI Study Patients With Advanced Cancer Dominant Liver Involvement</brief_title>
	<detailed_description>Cisplatin Liposomal Doxorubicin chemotherapy drug design fight cancer growth . If eligible take part study , enter treatment period divide cycle . Each cycle 28 day . You hospitalize receive chemotherapy . The night hospital admission receive fluid ( normal saline ) vein help avoid kidney side effect chemotherapy . The morning admission hospital take interventional radiology suite catheter place right groin . You must bedrest entire time catheter place . After procedure , go Nuclear Medicine test call `` flow study '' carry confirm right position catheter . After return room , nurse start chemotherapy . You first receive cisplatin groin catheter follow liposomal doxorubicin give one vein . The treatment last less three hour repeat every month . The catheter carefully tap move prevent come . Following completion chemotherapy infusion , intra-arterial catheter pull pressure apply groin 15 minute . In case , catheter remove immediately chemotherapy infusion complete . In case , catheter remain longer . You bedrest catheter remove . The catheter remove physician call . The catheter place remove treatment . Blood ( 2 teaspoon ) draw blood count liver function test dose sure researcher safely give liposomal doxorubicin . Since blood flow liver come portal vein , doctor try cause infarct ( like stroke ) liver artery follow injection cisplatin kill tumor cell . You see doctor advanced practice practitioner every day hospital . You hospitalize 5-7 day recovery immediate treatment related side effect . You continue receive therapy mention disease get bad intolerable side effect occur . At end participation study , scan see tumor grow shrinking , blood work ( 3 teaspoon ) make sure blood count electrolytes ( salts blood ) , kidney liver function safe level .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patients Histologically confirm diagnosis malignancy liver involvement dominant site metastasis ( 50 % tumor burden ) . 2 . Pediatric patient eligible discretion primary investigator . 3 . Performance Status Equivalent Grater 60 % Karnofsky 's Performance scale ( Requires occasional assistance able care need ) . 4 . Adequate Renal Function ( Serum CRE &lt; /= 1.5 mg/dL ) calculate Creatinine Clearance &gt; /= 50 ml/min ( Cockcroft Formula ) . 5 . Adequate Hepatic Function ( Total Bilirubin &lt; /= 1.5 mg/dL ALT &lt; /= 5 time upper normal reference value ) . 6 . Adequate Bone Marrow Function ( Absolute neutrophil count ( ANC ) &gt; /= 1.5 cells/uL ; number platelet ( PLT ) &gt; /= 100,000 cells/uL ) . 7 . At least three week previous cytotoxic chemotherapy day 1 HAI infusion . After targeted biologic therapy 5 halflives three week , whichever short . 8 . All Females Childbearing Age MUST negative urine serum Human chorionic gonadotropin human chorionic gonadotrophin ( hCG ) test unless prior hysterectomy menopause ( define age 55 six month without menstrual activity ) . 9 . Ability fully read , comprehend , sign inform consent form . In pediatric patient , informed consent form sign parent legal guardian . 10 . Patients germ cell tumor lymphoma MUST document progression disease prior enrollment . 1 . Clinical radiographic evidence Ascites . 2 . Pregnant female . 3 . Hypersensitivity platinum compound anthracyclines . 4 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 5 . Jaundice . ( Bilirubin &gt; 1.5 mg/dL ) . 6 . Bleeding Diathesis . ( Prothrombin time &gt; 20 secs International Normalized Ratio ( INR ) &gt; 2.0 ) . 7 . Portal vein thrombosis . 8 . Grade 2 Peripheral Neuropathy ( CTC V3.0 : Sensory alteration interfere function interfere ADL ) 9 . Medical History Clinical Evidence Congestive Heart Failure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Dominant Liver Involvement</keyword>
	<keyword>Hepatic Intraarterial Cisplatin</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Liposomal Doxorubicin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>Doxil</keyword>
	<keyword>Liposomal</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
</DOC>